|
Home | Technology News Search Engine:
|
|
|
|
Home: Technology News:
|
|
|
(IT-NEWSWIRE.COM, November 01, 2017 )
Global Anal Cancer Information, by type (Squamous cell carcinomas, Adenocarcinomas, perianal skin cancers, Melanomas and others), by treatment (chemotherapy, radio therapy, surgery and others), by end users (hospitals, clinics, research institutes and others) - Forecast to 2027
The Anal Cancer market is accruing and expected to gain further prominence over the forecast period mainly due to the growing prevalence of Anal Cancer, technological advancements and availability of effective treatments. According to a recent study report published by the Market Research Future, The global market of Anal Cancer is projected to accrue at a rapid pace during the forecast period (2017 – 2027). The Market is forecasted to account for upsurge accretions by 2027with a staggering CAGR during 2017 and 2027.
Sample Report Available at https://www.marketresearchfuture.com/sample_request/1530 .
Market for Anal cancer is growing attributed to the augmented prevalence of sexually transmitted diseases coupled with the increasing number of geriatric populace. Heady or changing lifestyles is the major reason responsible for increasing occurrences of the disease eventually contributing to the market growth. Other factors such as technological advancements and advent techniques to treat Anal cancer coupled with risen public and private sector funding in the field of drug development are fostering the market growth of Anal Cancer market. Additionally, increasing investment transpired by the key players in the field of R&D of novel drugs is providing impetus to the market growth.
However, cost associated with the Anal Cancer treatment which is slightly on the higher side, side effects of surgery like urinary incontinence & impotence and surgical risks like heart attack, stroke, and blood clots are some of the factors posing challenges to the market growth. Also, Loss of patent protection for drugs is considered as one of the major factor impeding the market growth.
Non-operative management of anal cancer is an emerging treatment approach that aims to enable carefully selected patients to avoid the morbidity of radical surgical resection, while benefiting from the same excellent rates of tumour control achieved with radical surgery–based combined-modality therapy. The success of Non-operative management in this setting is based on the accurate assessment of tumour eradication after chemoradiotherapy, without pathologic verification. Therefore, clinical evidence of complete response based on physical examination, endoscopic procedures, and imaging must be utilized as a marker to predict for pathologic complete response and thus help select the patients who are most appropriate for Non-operative management. Initial evidence from retrospective and prospective single-arm and cohort studies has demonstrated high rates of local control and disease-free survival with Non-operative management of Anal cancer, compared with historical results of combined-modality therapy. Several trials and registries are prospectively investigating Non-operative management vs. standard treatment of Anal cancer. At this time, combined-modality therapy with total mesorectal excision remains the standard of care for patients with locally advanced Anal cancer; Non-operative management should not be routinely offered outside of clinical trials.
According to the National Cancer Institute; People with HIV are 19 times more likely to be diagnosed with anal cancer than those without HIV.
Browse complete report at https://www.marketresearchfuture.com/reports/anal-cancer-market .
Human papilloma virus (HPV) vaccines have proven to be highly effective protection and believed that the HPV vaccines can protect both males and females against 80 per cent anal cancers. The incidence of HPV-related carcinomas has increased in anal cancers. Although the effect of the vaccine on adults who have already encountered high-risk strains of HPV is unclear, the aggressiveness of anal and other HPV cancers warrant the change.
Anal Cancer Market – Competitive Analysis
Characterized by the presence of several major players, having international recognition; the global market of Anal Cancer appears to be highly fragmented and competitive. Marketers compete based upon price and brand reinforcement. Well established players incorporate acquisition, collaboration, partnership, expansion, and technology launch in order to gain competitive advantage in this market and to maintain their market position.
Anal Cancer Market – Segments
The Anal Cancer Market is segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation By Types : Comprises Squamous Cell Carcinomas, Adenocarcinomas, Perianal Skin Cancers, Melanomas and other.
Segmentation By Treatment : Comprises Chemotherapy, Radio Therapy, Surgery and others.
Segmentation By End Users : Comprises Hospitals, Clinics, Research Institutes and others.
Segmentation By Regions : Comprises Geographical regions - North America, Europe, APAC and Rest of the World.
Ask question to expert at https://www.marketresearchfuture.com/enquiry/1530 .
Anal Cancer Market – Regional Analysis
Globally North America is the largest market for cervical dystonia. The North American market for Anal Cancer is expected to grow at a substantial CAGR and is expected to reach at astronomical amounts by the end of the forecasted period. Because of proper healthcare facilities treatment for anal cancer is possible in these countries.
Europe is expected to be the second-largest market for Anal Cancer which is expected to grow at a considerable CAGR.
Contact:
Market Research Future
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@Marketresearchfuture.Com
Marketresearchfuture
Market Research Future
+1 (646) 845 9349
sales@wiseguyreports.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
|
Technology News Headlines
|
|
|
|
|
Technology Business Video Feed
|
|
More Technology Video Feeds
|
|
|
